Akebia Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 167
- Market Cap
- $319.6M
- Website
- http://www.akebia.com
- Introduction
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded...
Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT03054350
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 3554
- Registration Number
- NCT02892149
- Locations
- 🇺🇸
AMPM Research Clinic, Miami, Florida, United States
🇬🇧Research Site, Doncaster, South Yorkshire, United Kingdom
🇺🇦Research Site #1, Cherkassy, Ukraine
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 369
- Registration Number
- NCT02865850
- Locations
- 🇺🇦
Research Site, Zhytomyr, Ukraine
🇺🇸Research Site #1, Chattanooga, Tennessee, United States
🇷🇺Research Site #2, Kemerovo, Russian Federation
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Conditions
- Interventions
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1725
- Registration Number
- NCT02680574
- Locations
- 🇷🇸
Research Site #3, Belgrade, Serbia
🇿🇦Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦Research Site #2, Durban, KwaZulu-Natal, South Africa
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 1751
- Registration Number
- NCT02648347
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
🇿🇦Research Site #1, Durban, KwaZulu-Natal, South Africa
🇿🇦Research Site #2, Durban, KwaZulu-Natal, South Africa
Effect of AKB-6548 on the Pharmacokinetics of Celecoxib
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT02502500
Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT02412449
Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT02327546
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 94
- Registration Number
- NCT02260193
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT02062203